EVOLUTION OF THE SEVERITY OF SYMPTOMS IN PATIENTS WITH COVID-19 TREATED WITH ATAZANAVIR AND IVERMECTIN: a prospective cohort study

• Autor(a) principal: Milanez Oliveira, Francisco Braz
• Data de Publicação: 2023
• Outros Autores: Primo, Maísa Guimarães Silva, Lira, Vanessa Brito de Carvalho, Parente, José Miguel Luz, Pinheiro Ferreira, Paulo Michel, Martins , Maria do Carmo de Carvalho, Oliveira, Beatriz Fátima Alves de, Mallet, Jacenir Reis dos Santos
• Tipo de documento: Artigo
• Idioma: por
• Título da fonte: Revista Enfermagem Atual In Derme
• Texto Completo: https://revistaenfermagematual.com/index.php/revista/article/view/1655
• topic: Sinais e Sintomas; Sulfato de Atazanavir; Ivermectina; COVID-19; Signos y Síntomas; Sulfato de Atazanavir; Ivermectina; COVID-19; Signs and Symptoms; Atazanavir Sulfate; Ivermectin; COVID-19

Objective: To evaluate the effect of pharmacological therapies with Atazanavir and Ivermectin on the evolution of severity of COVID-19 symptoms. Method: A prospective, longitudinal, descriptive and analytical cohort observational study was carried out, with 87 symptomatic outpatients, followed in two Basic Health Units of reference for COVID-19 care in Teresina-Piauí, Brazil, in the period of November to April 2021. Reverse transcription polymerase chain reaction (RT-PCR) tests were performed to confirm the suspected infection with the new coronavirus, in addition to sociodemographic, somatoscopic, clinical and hematological evaluation. Results: the cohorts consisted of 35 participants in the control group, 33 in the Atazanavir group and 19 in the Ivermectin group, with a prevalence of males, young adults, low-income and overweight. The most frequent symptoms reported during COVID-19 infection were: Cough (n=67), Loss of appetite (n=59), Fever (n=57), Coryza (n=45), Diarrhea (n=42) , Headache (n=39), Dizziness (n=35), Nausea (n=33), Cold skin (n=32), Palpitations (n=26) and Mood Change (n=24). There was evidence of normality patterns between the inflammatory parameters in the three cohorts and leukocyte alteration and neutrophilia in the cohorts that received the interventions. There was no difference in the evolution of symptom severity in patients with COVID-19 treated with Atazanavir and Ivermectin compared to the control group. The Ivermectin-treated vs Control cohort had an increased risk of gastrointestinal complications. Conclusions: The results do not support the use of ivermectin and atazanavir to reduce the severity of COVID-19 symptoms.